With no explanation, label text_A→text_B with either "not_related" or "related".
text_A: Ayn Rand supported self-government based on voluntary institutions.
text_B: Liraglutide -LRB- NN2211 -RRB- is a long-acting glucagon-like peptide-1 receptor agonist , binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion .. glucagon-like peptide-1 receptor agonist. glucagon-like peptide-1 agonist. endogenous. endogenous. metabolic. metabolic. hormone. hormone. GLP-1. glucagon-like peptide-1 agonist. insulin. insulin. Marketed under the brand name Victoza , it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes .. injectable drug. Injection ( medicine ). Novo Nordisk. Novo Nordisk. type 2 diabetes. type 2 diabetes. In 2015 , Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition .. Novo Nordisk. Novo Nordisk. comorbid. Comorbidity. The product was approved for treatment of type 2 diabetes by the European Medicines Agency -LRB- EMA -RRB- on July 3 , 2009 , and by the U.S. Food and Drug Administration -LRB- FDA -RRB- on January 25 , 2010 .. type 2 diabetes. type 2 diabetes. European Medicines Agency. European Medicines Agency. U.S. Food and Drug Administration. U.S. Food and Drug Administration. FDA. FDA. More recently , Liraglutide was approved by the FDA on December 23 , 2014 and by the European Medicines Agency on January 23 , 2015 , for adults with a body mass index -LRB- BMI -RRB- of 30 or greater -LRB- obesity -RRB- or a BMI of 27 or greater -LRB- overweight -RRB- who have at least one weight-related condition .. European Medicines Agency. European Medicines Agency. FDA. FDA
not_related.